Who owns GOOGLWhat GOOGL owns
What Alphabet Inc. owns
The company's own 13F portfolio · as of 2026-06-30 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F
$99.08B
disclosed stock portfolio
28
positions
95%
in SPCX
Positions, as of 2026-06-30
ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | SPCXSPACE EXPLORATION TECHN CORP | 551.2M | $94.18B | 95% |
| 2 | PLPLANET LABS PBC | 35.2M | $1.17B | 1.2% |
| 3 | ASTSAST SPACEMOBILE INC | 8.9M | $794.7M | 0.8% |
| 4 | CMECME GROUP INC | 3.5M | $769.4M | 0.8% |
| 5 | ARMARM HOLDINGS PLC | 2.0M | $695.2M | 0.7% |
| 6 | RVMDREVOLUTION MEDICINES INC | 2.9M | $551.8M | 0.6% |
| 7 | FRSHFRESHWORKS INC | 16.2M | $164.0M | 0.2% |
| 8 | PARABILIS MEDICINES INC | 4.9M | $134.6M | 0.1% |
| 9 | TEMTEMPUS AI INC | 1.6M | $89.9M | 0.1% |
| 10 | GTLBGITLAB INC | 2.7M | $83.2M | 0.1% |
| 11 | PATHUIPATH INC | 7.0M | $76.5M | 0.1% |
| 12 | ETHOS TECHNOLOGIES INC | 3.6M | $65.7M | 0.1% |
| 13 | PRIME MEDICINE INC | 16.6M | $61.1M | 0.1% |
| 14 | FERVO ENERGY CO | 1.8M | $51.5M | 0.1% |
| 15 | PAYPAY CORP | 3.1M | $44.8M | 0% |
| 16 | MAZEMAZE THERAPEUTICS INC | 1.4M | $41.4M | 0% |
| 17 | RLAYRELAY THERAPEUTICS INC | 1.4M | $26.4M | 0% |
| 18 | BRIDGEBIO ONCOLOGY THERAPEUT | 2.8M | $21.5M | 0% |
| 19 | OSCROSCAR HEALTH INC | 481,988 | $13.7M | 0% |
| 20 | BEAMBEAM THERAPEUTICS INC | 321,604 | $11.0M | 0% |
| 21 | VERAVERA THERAPEUTICS INC | 241,264 | $10.4M | 0% |
| 22 | SANASANA BIOTECHNOLOGY INC | 2.8M | $9.8M | 0% |
| 23 | GLUEMONTE ROSA THERAPEUTICS INC | 372,474 | $9.0M | 0% |
| 24 | LYELL IMMUNOPHARMA INC | 293,256 | $4.1M | 0% |
| 25 | FIGFIGMA INC | 215,582 | $3.9M | 0% |
| 26 | SPERO THERAPEUTICS INC | 889,979 | $2.0M | 0% |
| 27 | HYPERFINE INC | 898,720 | $1.2M | 0% |
| 28 | AUTOLUS THERAPEUTICS PLC | 698,262 | $1.1M | 0% |
Source: SEC Form 13F-HR filed by Alphabet Inc. (CIK 1652044), reporting period 2026-06-30. Values are quarter-end filed marks. Research, not investment advice.